Toxys opens US office and production facility to accelerate growth
The opening of an office and production facility in the US supports the company’s growth strategy to become the global leading supplier of expert mechanistic in vitro chemical safety assays. These assays provide animal-free safety testing of novel medicines, chemicals, and consumer products. Toxys is a recognized expert in the fields of genotoxicity, developmental toxicology, and mechanistic toxicity testing and has developed the unique ToxTracker®, ReproTracker® and ToxProfiler™ assays.
“The decision to expand our presence into the United States was a logical step in our business growth strategy,” said Giel Hendriks, president. “We have made important progress on development of innovative animal-free tests for drug and chemical safety testing. With our new US facilities, we are ready to further expand our business globally and continue to work on the development of novel solutions for toxicological research”.
Toxys is a global leading expert that develops and offers a broad spectrum of unique animal-free laboratory tests for the safety assessment. Toxys was founded in 2014 as a spin-off from the Leiden University Medical Center, The Netherlands and has its European headquarter and state-of-the-art laboratory facilities located at the Leiden Bio Science Park and a sales office in New York. Toxys is an expert in toxicological research with a mission to improve animal-free safety testing by creating mechanistic in vitro chemical safety tests to meet the needs for safer medicines, chemicals, and cosmetics. Toxys is currently working with 7 out of top 10 global Pharma companies and several major chemical, cosmetics and food multinationals and is highly valued for its scientific expertise, high-quality results, and responsiveness.
President Toxys Inc.